Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent
Tóm tắt
The plasma pharmacokinetics of the antitumor antibiotic geldanamycin (GM; NSC 122750), a naturally occurring benzoquinoid ansamycin, was characterized in mice and a beagle dog. Concentrations of GM well above 0.1 μg/ml, which was typically effective against neoplastic cell lines responsive to the drug in vitro, were achieved in the plasma of the mice and the dog treated by i.v. injection. However, the systemic duration of the drug was relatively short. Plasma levels decayed below 0.1 μg/ml within 3–4 h after administration of the apparent maximum tolerated doses, which were approximately 20 mg/kg for the mice and 4 mg/kg for the dog. The drug exhibited linear pharmacokinetic behavior within the dose ranges studied. However, there were significant interspecies differences in its disposition. Whereas the mean biological half-life of GM was slightly longer in the mice (77.7 min) than in the dog (57.9 min), its mean residence time in the dog (46.6 min) was more than twofold greater than that observed in the mice (20.7 min). Nevertheless, the drug was cleared from plasma much faster by the dog (49.4 ml/min per kg) than by the mice (30.5 ml/min per kg). These apparent anomalies were principally associated with differences in the relative significance of the terminal phase upon overall drug disposition. The liver appeared to be the principal target organ of acute drug toxicity in the dog. Doses of 2.0 and 4.2 mg/kg both produced elevations in serum levels of the transaminases and other indicators of liver function characteristic of acute hepatic necrosis. Additional effects included symptoms of minor gastrointestinal toxicity and alterations in serum chemistry parameters consistent with less severe nephrotoxicity. Drug-related toxicity appeared to be reversible. In consideration of the potential for acute hepatotoxic reactions to GM, as well as to the other benzoquinoid ansamycins based upon structural analogy, additional pharmacological and therapeutic information is required to ascertain whether these compounds are viable candidates for clinical development.
Tài liệu tham khảo
Benet LZ (1972) General treatment of linear mammillary models with elimination from any compartment as used in pharmacokinetics. J Pharm Sci 61: 536
Boyd MR (1989) Status of the NCI preclinical antitumor drug discovery screen. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology updates, vol 3, number 10. Lippincott, Philadelphia, pp 1–12
De Boer C, Meulman PA, Wnuk RJ, Peterson,DH (1970) Geldanamycin, a new antibiotic. J Antibiot 23: 442
Frank LA (1990) Clinical pharmacology of rifampin. J Am Vet Med Assoc 197: 114
Fukazawa H, Li PM, Yamamoto C, Murakami Y, Mizuno S, Uehara Y (1991) Specific inhibition of cytoplasmic protein tyrosine kinases by herbimycin A in vitro. Biochem Pharmacol 42: 1661
Garcia R, Prikh NU, Saya H, Gallick GE (1991) Effect of herbimycin A on growth and pp60c-src activity in human colon tumor cell lines. Oncogene 6: 1983
Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn, Marcel Dekker, New York, p 409
Grever MR, Schepartz SA, Chabner BA (1992) The National Cancer Institute: cancer drug discovery and development program. Semin Oncol 19: 662
Grosset J, Leventis S (1983) Adverse effects of rifampin. Rev Infect Dis 5: 5440
Hamaguchi M, Xiao H, Uehara Y, Ohnishi Y, Nagai Y (1993) Herbimycin A inhibits the association of p60v-src with the cytoskeletal structure and with phosphatidylinositol 3′ kinase. Oncogene 8: 559
Honma Y, Okabe-Kado J, Hozumi M, Uehara Y, Mizuno S (1989) Induction of erythroid differentiation of K562 human leukemic cells by herbimycin A, an inhibitor of tyrosine kinase activity. Cancer Res 49: 331
Honma Y, Kaskukabe T, Hozumi M, Shibata K, Omura S (1992) Effects of herbimycin A derivatives on growth and differentiation of K562 leukemic cells. Anticancer Res 12: 189
Honma Y, Okabe-Kado J, Kasukabe T, Hozumi M, Kodama H, Kajigaya S, Sda T, Miura Y (1992) Herbimycin A, an inhibitor of tyrosine kinase, prolongs survival of mice inoculated with myeloid leukemia C1 cells with high expression ofv-abl tyrosine kinase. Cancer Res 52: 4017
Insel PA (1990) Analgesic-antipyretics and antiinflammatory agents; drugs employed in the treatment of rheumatoid arthritis and gout. In: Gilman AG, Rall TW, Nies AS, Taylor P (eds) The basis of therapeutics, 8th edn, Pergamon Press, New York, pp 657–658
Iwai Y, Nakagawa A, Sadakane N, Omura S, Oiwa H, Matsumoto S, Takahashi M (1980) Herbimycin B, a new benzoquinoid ansamycin with anti-TMV and herbicidal activities. J Antibiot 33: 1114
Li LH, Clark TD, Cowie CH, Rinehart KL Jr (1977) Effect of geldanamycin and its derivatives on RNA-directed DNA polymerase and infectivity of rauscher leukemia virus. Cancer Treat Rep 61: 815
Lin LZ, Blasko G, Cordell GA (1988)1H-NMR analysis of herbimycins and dihydro-herbimycins. J Nat Prod 51: 1161
Miner DJ, Kissinger PT (1979) Evidence for the involvement ofN-acetyl-p-quinoneimine in acetaminophen metabolism. Biochem Pharmacol 28: 3285
Mitchell JR, Jollow DJ, Potter WZ, Gillette JR, Brodie BB (1973) Acetaminophen-induced hepatic necrosis. IV. Role of drug metabolism. J Pharmacol Exp Ther 187: 185
Muroi M, Izawa M, Kosai Y, Asai M (1980) Macbecins I and II, new antitumor antibiotics II. Isolation and characterization. J Antibiot 33: 205
Muroi M, Haibara K, Asai M, Kamiya K, Kishi T (1981) The structures of macbecin I and II Tetrahedron 37: 1123
Omura H, Hasegawa Y, Ikai T (1979) Herbimycin, a new antibiotic produced by a strain ofStreptomyces. J Antibiot 32: 255
Omura S, Miyano K, Nakagawa A, Sano H, Komiyama K, Umezawa I (1984) Chemical modification and antitumor activity of herbimycin A. 8,9-Epoxide, 7,9-cyclic carbamate, and 17 or 19-amino derivatives. J Antibiot 37: 1264
Ono Y, Kozai Y, Ootsu K (1982) Antitumor and cytocidal activities of a newly isolated benzenoid ansamycin, macbecin I. Gann 73: 938
Peehl DM (1992) Culture of human prostatic epithelial cells. In: Freshney IA (ed) Culture of epithelial cells, Wiley Liss, New York, pp 159–180
Peehl D, Erickson E, Malspeis L, Orr J, Mayo J, Camalier R, Monks A, Cronise P, Paull K, Grever MR (1993) Prostate cancer: NCI drug discovery efforts (abstract). Proc Am Assoc Cancer Res 34: 369
Rinehart KL Jr, Shield LS (1976) Chemistry of the ansamycin antibiotics. Fortschr Chem Org Naturst 33: 231
Rosenkrantz H, Hadidian Z, Seay H, Mason MM (1963) Dimethyl sulfoxide: its steroid solubility and endocrinologic and pharmacologic-toxicologic characteristics. Cancer Chemother Rep 31: 7
Rowland M, Tucker G (1980) Symbols in pharmacokinetics. J Pharmacokinet Biopharm 8: 497
Sano H, Komiyama K, Nakagawa A, Omura S (1986) Chemical modification of herbimycin A. Synthesis andin vivo antitumor activities of halogenated and other related derivatives of herbimycin A. J Antibiot 39: 415
Sasaki K, Rinehart KL Jr, Slomp G, Grostic MF, Olson EC (1970) Geldanamycin. I. Structure assignment. J Am Chem Soc 92: 7591
Sasaki K, Yasuda H, Onodera K (1979) Growth inhibition of virus transformed cells in vitro and antitumor activity in vivo of geldanamycin and its derivatives. J Antibiot 32: 849
Uehara Y, Hori M, Takeuchi T, Umezawa H (1986) Phenotypic change from transformed to normal induced by benzoquinonoid ansamycins accompanies inactivation of p60src in rat kidney cells infected with Rous sarcoma virus. Mol Cell Biol 6: 2198
Uehara Y, Murakami Y, Sugimoto Y, Mizuno S (1989) Mechanism of reversion of Rous sarcoma virus transformation by herbimycin A: reduction of total phosphotyrosine levels due to reduced kinase activity and increased turnover of p60v-src1. Cancer Res 49: 780
Uehara Y, Fukazawa H, Murakami Y, Mizuno S (1989) Irreversible inhibition of v-src tyrosine kinase activity by herbimycin A and its abrogation by sulfhydryl compounds. Biochem Biophys Res Commun 163: 803
Whitesell L, Shifrin SD, Schwab G, Neckers LM (1992) Benzoquinonoid ansamycins possess selective tumoricidal activity unrelated tosrc kinase inhibition. Cancer Res 52: 1721
Willson JE, Brown DE, Timmens EK (1965) A toxicological study of dimethyl sulfoxide. Toxicol Appl Pharmacol 7: 104
Wintrobe MM, Thorn GW, Adams RD, Braunwald E, Isselbacher KJ, Petersdorf RG (eds.) (1972) Principles of internal medicine, 7th edn, McGraw-Hill, New York, pp 1200–1202, 1513–1519, 1912
Yamaki H, Suzuki H, Choi EC, Tanaka N (1982) Inhibition of DNA synthesis in murine tumor cells by geldanamycin, an antibiotic of the benzoquinoid ansamycin group. J Antibiot 35: 886